STCube Applies for Phase 1 Clinical Trial of Immuno-Oncology Drug

[Asia Economy Reporter Minwoo Lee] STCube announced on the 6th that it has applied to the Ministry of Food and Drug Safety for a Phase 1 clinical trial plan of the immuno-oncology drug hSTC810. The clinical trials will be conducted at three hospitals in the United States and one hospital in Korea.

The company stated, "We plan to evaluate the tolerability and safety of hSTC810 monotherapy and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD)." They added, "We will confirm the pharmacokinetic characteristics and conduct a preliminary assessment of immunogenicity and anticancer efficacy."